single-dose pharmacokinetics of dasatinib in subjects with hepatic impairment compared to healthy adult subjects

Trial Profile

single-dose pharmacokinetics of dasatinib in subjects with hepatic impairment compared to healthy adult subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 13 Apr 2011

At a glance

  • Drugs Dasatinib (Primary)
  • Indications Acute lymphoblastic leukaemia; Breast cancer; Chronic lymphocytic leukaemia; Chronic myeloid leukaemia; Colorectal cancer; Glioblastoma; Leukaemia; Malignant melanoma; Mesothelioma; Multiple myeloma; Myelodysplastic syndromes; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Prostate cancer
  • Focus Pharmacokinetics
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 13 Apr 2011 Actual end date (Aug 2007) added as reported by ClinicalTrials.gov.
    • 08 Nov 2007 The expected completion date for this trial is now 1 Aug 2007.
    • 01 Nov 2007 Status changed from in progress to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top